関連する実験動画
Updated: Sep 10, 2025

08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
9.9K
犬の心臓機能に対するドクソルビシンの影響: 排泄分数の変化と心不全のリスク
Gustavo Cavinato Herrera1, Luiz Ricardo Soldi1, Leandro Machado Oliveira2
1Institute of Biomedical Science, Federal University of Uberlândia-UFU, Uberlândia, Minas Gerais, Brasil.
Veterinary medicine and science
|August 25, 2025
まとめ
犬のドクソルビシン治療は,エジェクション分数 (EF) を低下させ,重大な心臓損傷を引き起こす可能性があります. このレビューは,薬物の
科学分野:
- 獣医学
- 心臓病科
- 薬理学について
背景:
- ドクソルビシンは,獣医学における重要な抗腫瘍抗生物質である.
- 心臓の毒性は主要な副作用であり,心不全と治療中止につながる可能性があります.
- 犬の心臓機能に対するドクソルビシンの影響の評価は,治療管理において極めて重要です.
研究 の 目的:
- ドクソルビシンが犬のエジェクション分数 (EF) に及ぼす心臓毒性効果を体系的に検討し,メタ分析する.
- ドクソルビシンによる心臓毒性に対する異なる投与経路の影響を評価する.
- がん治療を受けている犬の心臓機能に対するドクソルビシンの影響に関する証拠を合成する.
主な方法:
- 8つのデータベースで体系的な文献検索を行い,3587件の記事をスクリーニングしました.
- 犬におけるドクソルビシンプロトコルに関する15の適格な研究を含む.
- 試験方法論,結果,および偏差のリスクの評価,エコーカルディオグラフィの調査結果を含む.
主要な成果:
- 13件の研究では,投与経路によって毒性が異なる心臓の変化が報告されました.
- 冠内ドクソルビシン投与はより有毒で,すべての6つの研究で心不全を引き起こした.
- 静脈内投与は9件のうち6件で心不全を引き起こし,メタ分析した4件で平均EF減少が21. 24%であった.
結論:
- ドクソルビシンは心臓機能を著しく低下させ,心臓病を悪化させる.
- 投与経路はドクソルビシンの心臓毒性効果の重さに重大な影響を及ぼします.
- 獣医の患者の心臓の健康に対するドクソルビシンの影響を管理するには,患者の厳密なモニタリングが不可欠です.
関連する概念動画
Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
Heart Failure II: Pathophysiology
38
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
38
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure I: Introduction
54
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
54
Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434

